A pragmatic comparison of montelukast and ketotifen in children with asthma in a resource limited setting
Romanian Journal of Pediatrics · 31.03.2026 · 75 (1) · 28
DOI: 10.37897/rjp.2026.1.7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Romanian Journal of Pediatrics, online erschienen am 31.03.2026. Verfasst von Tarana Bai Maheshwari und 5 weiteren Autor:innen.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Asthma is a common chronic childhood illness that causes recurrent symptoms and reduced quality of life. In low-resource settings, oral therapies such as montelukast and ketotifen are frequently used. This study compared their effects on asthma severity and pulmonary function in children. Methodology. A randomized, open-label, pragmatic comparative study was conducted at Isra University Hospital, Hyderabad, from March to July 2025. One hundred children aged 5-15 years with clinically stable mild to moderate asthma were enrolled; baseline severity was additionally characterized using PASS, which may reflect current clinical status at presentation. Participants were then randomly assigned to receive montelukast 5 mg nightly (n = 50) or ketotifen 1 mg daily (n = 50) for 3 months. The primary outcome was change in Pediatric Asthma Severity Score (PASS), used pragmatically as a longitudinal measure of symptom burden. Secondary outcomes included FEV₁ and the FEV₁/FVC ratio. Clinically meaningful improvement was evaluated using responder analysis (PASS reduction ≥2 points; FEV₁ improvement ≥10%). Data were analyzed using SPSS version 26.
Results
Baseline characteristics were comparable between groups. After 3 months, montelukast showed statistically greater improvement in asthma severity scores than ketotifen (mean PASS reduction 3.16 ± 0.43 vs 2.40 ± 0.53; between-group difference 0.76, 95% CI: 0.57-0.95; p < 0.001). Pulmonary function improved in both groups, with greater gains in the montelukast group for FEV₁ (0.52 ± 0.14 L vs 0.37 ± 0.11 L) and the FEV₁/FVC ratio (0.047 ± 0.014 vs 0.031 ± 0.014; both p < 0.001). Clinically meaningful improvement was more frequent in the montelukast group (PASS ≥2 points: 84.0% vs 62.0%; FEV₁ ≥10%: 76.0% vs 56.0%). Both treatments were well tolerated, with only minor adverse events reported.
Conclusion
Montelukast modestly improved asthma severity scores and pulmonary function compared with ketotifen. These findings provide context-specific evidence for low-resource settings but should be interpreted cautiously because of the sample size, short follow-up, open-label design, and pragmatic outcome assessment approach.
Zitieren
APA
Maheshwari, T. B., Maheshwari, M., Memon, A., Javed, A., Aslam, R., & Hammad, M. (2026). A pragmatic comparison of montelukast and ketotifen in children with asthma in a resource limited setting. Romanian Journal of Pediatrics, 75(1), 28. https://doi.org/10.37897/rjp.2026.1.7
Vancouver
Maheshwari TB, Maheshwari M, Memon A, Javed A, Aslam R, Hammad M. A pragmatic comparison of montelukast and ketotifen in children with asthma in a resource limited setting. Romanian Journal of Pediatrics. 2026;75(1):28. doi:10.37897/rjp.2026.1.7
BibTeX
@article{Maheshwari2026,
author = {Maheshwari, Tarana Bai and Maheshwari, Mahaveer and Memon, Aslam and Javed, Aisha and Aslam, Rabat and Hammad, Muhammad},
title = {A pragmatic comparison of montelukast and ketotifen in children with asthma in a resource limited setting},
journal = {Romanian Journal of Pediatrics},
year = {2026},
volume = {75},
number = {1},
pages = {28},
doi = {10.37897/rjp.2026.1.7}
}
EUVIMED